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Introduction
Colorectal cancer is one of the most common cancer sites
diagnosed throughout the world, accounting for approx.
10% of all incident cases [1]. About 50-60% of patients
are cured by surgery and adjuvant chemotherapy. The
remaining group will, sooner or later, need palliative
chemotherapy [2, 3]. The most common chemothera-
peutic agent in the treatment of colorectal cancer is still
fluorouracil. The efficiency of this treatment is similar to
the treatment with new antifolate agents, like ralitrexed
(Tomudex) or capecitabine (Xeloda), depends on the
activity of thymidylate synthase (TS) [2, 4]. This enzyme is
responsible for the provision of thymidylate required for
DNA synthesis and repair [2, 5].
Multiple studies have shown that patients with high
levels of intratumoral TS expression in their cancers have
a significantly worse clinical outcome and worse response
to fluoropyrimidine-containing regimens as compared to
patients with cancers of a relatively low intracellular level.
However, the results of these studies are not consistent.
Currently, only the stage of disease is widely accepted as
a prognostic factor [6, 7].
In the present investigation, we have retrospectively
examined the prognostic value of thymidylate synthase
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A i m.  The aim of the study was to define the prognostic value of thymidylate synthase (TS) expression in colorectal cancer
(CRC), and its role as a predictor of the chemotherapeutic benefit in patients treated with fluorouracil (5-FU).
M a t e r i a l  a n d  m e t h o d s.  TS expression was immunohistochemically assessed on primary tumor archival specimens from
120 patients with CRC.
R e s u l t s.  For the entire study population the univariate analysis revealed that TNM stage, surgical margin, vessel invasion,
and TS expression were significant prognostic factors. In a subgroup treated with 5-FU (n=98) overall survival correlated with
tumor location, TNM stage, surgical margin, and TS expression. Multivariate analysis demonstrated that tumor stage, TNM
stage, and TS expression were independent prognostic factors. In the subgroup treated with 5-FU only tumor location, tumor
stage, and TNM stage correlated with survival. 
C o n c l u s i o n s.  TS expression in primary tumors was a significant, independent prognostic factor in colorectal cancer. The
evaluation of its predictive role requires further investigations.
Znaczenie syntetazy tymidylowej w rokowaniu u chorych z rakiem jelita grubego
C e l.  Celem pracy by∏o okreÊlenie wartoÊci prognostycznej i predykcyjnej ekspresji syntetazy tymidylowej (TS) w raku jelita
grubego.
M a t e r i a ∏  i m e t o d y.  Ekspresj´ TS oznaczano immunohistochemicznie w bloczkach parafinowych z guzów pierwotnych
u 120 chorych z rakiem jelita grubego.
W y n i k i.  Analiza jednocechowa wykaza∏a, ˝e w grupie 120 chorych na ca∏kowite prze˝ycie wp∏ywa∏y istotnie: zaawansowanie
procesu nowotworowego, radykalnoÊç mikroskopowa zabiegu, obecnoÊç zatorów z komórek nowotworowych w naczyniach
oraz charakter ekspresji TS. W grupie 98 chorych leczonych chemicznie fluorouracylem na prze˝ycie wp∏ywa∏y istotnie:
lokalizacja guza, zaawansowanie procesu, radykalnoÊç mikroskopowa zabiegu oraz charakter ekspresji TS. Analiza
wielocechowa wykaza∏a, ˝e g∏´bokoÊç nacieku raka, stopieƒ zaawansowania wg TNM oraz charakter ekspresji TS sà
istotnymi niezale˝nymi czynnikami rokowniczymi. W grupie chorych leczonych fluorouracylem jedynie lokalizacja nowotworu,
g∏´bokoÊç nacieku i zaawansowanie procesu nowotworowego sà niezale˝nymi istotnymi czynnikami rokowniczymi.
W n i o s k i. Charakter ekspresji TS jest istotnym, niezale˝nym czynnikiem rokowniczym w raku jelita grubego. OkreÊlenie roli
predykcyjnej TS wymaga dalszych badaƒ.
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expression in primary colorectal cancer, and the role of
this expression as a predictor of the chemotherapeutic
benefit in patients treated with fluorouracil.
Material and methods
Tumor specimens examined for TS expression were obtained
from 120 patients with colorectal cancer, who were diagnosed
between 1992 to 2001. Their characteristics according to sex,
age, localization of tumor, histology and grading, TNM and
Dukes classification, microscopic radical margin of surgery and
vessel invasion are listed in Table I. Mean duration of follow-up
was 28.6 months (range: 0.3 – 114 months; median: 28 months),
from August 1992 to March 2003.
Among 120 patients after radical surgery of the primary
tumor 98 (81.7%) were treated with 5-FU-based chemotherapy
regimens (45 were treated with chemo-radiotherapy in 1999-
2001; 36 with adjuvant chemotherapy and 17 as palliation in
disseminated disease). 61 patients received leucovorin-
modulated 5-fluorouracil, 25 patients 5-FU plus leucovorin and
levamisol, and 12 patients were treated with 5-FU and levamisol.
12 patients with Dukes A and B cancer were without any
adjuvant treatment.
T S  i m m u n o h i s t o c h e m i c a l  a n a l y s i s
Paraffin-embedded, formalin fixed specimens of the resected
tumors were analyzed immunohistochemically [2-4, 6]. Two
sections (4 µm thick), taken from different parts of the primary
tumor were analyzed for TS expression.
Tissue specimens were first deparaffinized in 100% xylene
and rehydrated through graded alcohol solutions. Endogenous
peroxidase activity was inhibited by incubating the slides in 3%
hydrogen peroxidase for 10 minutes, followed by a 5-minute
rinse in dH2O. The slides were heated in a microwave oven in
EDTA, pH 8.0, and stored in TBS (Tris-buffered saline) and
proteinase K. The tissues were incubated for 60 minutes with TS-
106 (mouse monoclonal antibody, Chemicon International,
Temecula, CA 92590) at room temperature at a 1:50 dilution.
The slides were washed with TBS and then incubated in DAKO
EnVision+TM, Peroxidase Mouse complex (DAKO Corporation,
USA) for 30 minutes. The slides were again washed a few times
with TBS and then incubated with AEC Substrate-chromogen
system (DAKO AEC) for 10 minutes. Following another wash
cycle, the tissues were counter-stained with hematoxilin
(DAKO). The slides were rinsed and closed in glicerogel.
T i s s u e  e v a l u a t i o n
Each slide was examined for intensity and staining pattern by two
investigators, who were blinded to all clinical information.
Discrepant scores (about 5% of cases) were resolved by
consensus.
Intensity scores ranged from 0 to 3 (0=no staining, 1=trace
staining, 2=definite staining of light to moderate intensity, and
3=bright intensity). The staining pattern was either F (focal)
or D (diffuse). Samples with 50% or fewer malignant cells
stained at the assigned intensity level were considered F (0=less
than 25% cells stained, 1=25-50% cells stained). Samples with
more than 50% of stained cells were scored as D (2=50-75%
cells and 3=more than 75% cells stained). Examples of the TS
staining pattern are presented in Figures 1-4.
S t a t i s t i c a l  a n a l y s i s
The outcome variable was overall survival (OS) with death from
any cause as an end point. Follow-up time was measured from
the date of surgery.
The analysis was performed for the entire study population
(n=120) and in the subgroup treated with fluorouracil-based
chemotherapy at any time (n=98). Owing to the relatively small
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Table I. Characteristics of the group of 120 patients with colorectal
cancer treated between the years 1992 and 2001
Characteristic No. of patients % of patients
Sex
Male 74 62%
Female 46 38%
Age (median age 59,4 years)
≤ 60 years 64 53.3%
> 60 years 56 46.7%
Localization
colon 42 35%
rectum 78 65%
Histology
Adenocarcinoma 117 97.5%
other 3 2.5%
Tumor differentiation
G1 63 52.5%
G2 56 46.7%
G3 1 0.8%
Tumor size pT
pT2 12 10%
pT3 72 60%
pT4 36 30%
Lymph node metastases pN
pN0 64 53.3%
pN1 39 32.5%
pN2 17 14.2%
Distant metastases
M0 101 84.2%
M1 19 15.8%
Dukes’ stage / TNM stage
A / I° 4 3.3%
B / II° 52 43.3%
C / III° 45 37.5%
D / IV° 19 15.8%
Radical resection margin
yes 73 60.8%
no 47 39.2%
Vessel invasion
no 96 80%
yes 24 20% Figure 1. The focal TS staining pattern (TS=0)
numbers of patients treated with chemo-radiotherapy, adjuvant
and palliative chemotherapy we did not perform the analysis in
these particular subgroups. Survival distributions were estimated
using the Kaplan-Meier method.
In the univariate analysis the possible relationships between
overall survival and age, sex, localization, histological grading,
TNM and Dukes’ stage, the microscopic radical margin of
surgery, vessel invasion, TS staining intensity and pattern were
examined by log-rank test. Multivariate analysis was performed
using Cox’s regression model. All P values below 0.05 were
considered statistically significant.
Results
In the univariate analysis for the entire study population
(n=120) overall survival was significantly linked to Dukes’
and TNM stage, the microscopic radical margin of
surgery, the vessel invasion and the staining pattern of
TS (p<0.05 – Table II). Multivariate analysis showed that
only the stage and the staining pattern of TS remained as
the significant prognostic factors (Table III).
In the subgroup treated with 5-FU-based therapy at
any time (n=98) the univariate analysis revealed the
prognostic importance of localization, TNM and Dukes’
stage, the microscopic radical margin of surgery and the
staining pattern of TS (Table II). By multivariate analysis
localization, TNM and Dukes’ stage remained as
important prognostic factors of survival (p<0.05). The
staining pattern of TS had no significant prognostic value
in this group (p=0.0853, Table III).
Discussion
In 1994 Johnston et al. [8] were the first to suggest that
the level of TS expression in primary colorectal cancer
may be of prognostic importance. During the next 10
years at least 28 studies concerning this problem were
published [2-29]. 16 of them confirmed the observations
of Johnston et al. [2, 4-6, 8, 9, 11, 12, 14-16, 18, 21, 23, 26,
28].
The results of our study confirm that the level of TS
expression in primary colorectal cancer correlates with
survival. Patients with a low level of TS have a better
overall survival compared with patients with high TS
levels. This observation was restricted only to the TS
diffuse staining pattern (Figure 5 and 6). Similarly as
Gonen et al. [18] and Allegra et al. [2] we were unable to
identify the prognostic role of TS staining intensity.
Multivariate analysis has demonstrated that the ability
of the TS diffuse staining pattern to predict survival was
independent of the tumor size and the stage of disease.
The results of our investigation seem to be resemble
most those presented by Allegra et al. [2]. They assessed
the TS staining pattern immunohistochemically and
divided patients into two groups with more or less than 50
% of cancer cells with TS expression (diffuse vs. focal TS
staining pattern). Similarly, TS expression was detected in
the primary tumors with the use of TS 106 monoclonal
antibody.
Gonen and others have estimated TS expression in
frozen samples of liver metastases with the use of
a polyclonal antibody [18]. Due to those technical diffe-
rences the results confirmed the prognostic significance of
thymidylate synthase in colorectal cancer.
The Edler et al. study revealed the prognostic value
of TS in the group of 862 patients with Dukes’ B and C
colorectal cancer [6]. The material and methods were
similar as in our study. Similarly, most of patients had
high TS level that correlated with overall survival. As in
our investigation Edler was not able to prove the prog-
nostic role of TS expression in the subgroup of patients
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Figure 3. The diffuse TS staining pattern (TS=2)
Figure 4. The diffuse TS staining pattern (TS=3)
Figure 2. The focal TS staining pattern (TS=1)
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Table II. Univariate overall survival analysis for examined parameters
Parameter All patients (n=120) Chemotherapy group (n=98)
n OS (%) P n OS (%) P
Sex
Male 74 63 .5160 58 64 .9041
Female 46 62 40 59
Age
≤ 60 years 64 64 .2027 56 61 .6604
> 60 years 56 60 42 62
Localization
colon 42 52 .1484 39 47.5 .0166*
rectum 78 69 59 72
Tumor differentiation
G1 63 73 .2357 49 73.5 .2277
G2 + G3 57 52 49 53
Tumor size pT
pT2 12 75 7 71.5
pT3 72 71 61 70
pT4 36 40 30 42
pT2+pT3 v. pT4 71 v 40 .0005* 70 v 42 .0029*
Lymph node metastases pN
pN0 64 77 .0054* 46 75 .0338*
pN1 + pN2 56 45 52 49
Distant metastases
M0 101 74 .0000* 81 75 .0000*
M1 19 0 17 0
Dukes’ stage / TNM stage
A+B / I° + II° 56 85 .00007* 38 86.5 .0003*
C+D / III° + IV° 64 2 60 45
Radical surgical margin
yes 73 75 .0031* 61 74 .0066*
no 47 40 37 32.5
Vessel invasion
no 96 70 .0018* 78 67 .0584
yes 24 36 20 43
TS intensity
Low (0, 1) 43 74 .1896 35 75 .0908
High (2, 3) 77 55 63 52
TS pattern
Focal (0, 1) 50 82 .0024* 40 85 .0013*
Diffuse (2, 3) 70 48 58 43.7
* significant difference (P<.05)
Table III. Cox’s regression model multivariate analyses with respect to overall survival in the entire study population (n=120) 
and in the group treated with 5FU-based chemotherapy (n=98)
Parameter All patients Chemotherapy group
n=120 n=98
HR** 95% CI P HR** 95% CI P
Localization
colon 1.0
rectum 1.91 1.12 – 2.70 .0452*
Tumor size pT
pT2 + pT3 1.0 1.0
pT4 1.82 1.43 – 2.22 .0028* 1.80 1.41 – 2.20 .0034*
TNM stage
I° + II° 1.0 1.0
III° + IV° 1.97 1.59 – 2.35 .0004* 6.52 5.30 – 7.74 .0026*
TS staining pattern
F (focal; 0, 1) 1.0 1.0
D (diffuse; 2, 3) 2.36 1.56 – 3.16 .0355* 2.44 1.42 – 3.46 .0853
* significant difference (P<. 05)
** HR, hazard ratio (HR = eβ, where e=2.71828); CI, confidence interval
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treated with adjuvant 5-FU chemotherapy. The earlier
observations of Edler and others in the group of colo-
rectal cancer patients with Dukes’ stage A-D revealed
that 5-year overall survival of patients with high TS
expression reached about 50% (in our study 48%) versus
85% in patients with low TS level (82% in our study)
[15].
Several previous reports have suggested that patients
whose primary tumors had low TS expression may be
more sensitive to 5-FU-based chemotherapy [3, 4, 6, 9, 10,
12, 13, 18-20, 22, 24].
There are also studies indicating that patients with
high TS levels may benefit from adjuvant 5-FU chemo-
therapy [6]. In this retrospective investigation we found
that patients with diffuse TS staining pattern had the
lesser but not significant benefit from the use of
5-FU chemotherapy compared with those patients
whose tumors contained the focal TS staining pattern.
However, the number of our patients in the chemo-
therapy group was relatively small.
Previous studies have demonstrated that in cases of
disseminated disease the high TS mRNA level and the
high TS protein expression assessed on the metastatic
tumor indicated resistance to treatment based on 5-FU
[11, 18, 20, 21]. Johnston et al. compared the TS
expression in the primary and metastatic tumors in
colorectal cancer patients and found a lack of correlation
between TS levels [3]. Aschele et al. assessed TS
expression immunohistochemically on the primary tumors
and liver metastases obtained from 18 patients with
colorectal cancer [10]. In 11 of 18 patients the TS
expression was different in primary and metastatic tumor,
and in 10 patients the TS level was lower in the metastasis
than in the primary site. Those results were observed only
in patients with metastatic disease treated with fluoro-
uracil. In our investigation among 98 patients treated
with 5-FU only 17 had metastatic colorectal cancer (all
with liver metastases). TS expression was assessed on the
primary tumors. Similarly as in the study of Aschele et al.,
where the high TS levels were observed in primary tumors
* significant difference (p<0.05)
Figure 5. The 5-year overall survival curve for thymidylate synthase (TS) staining pattern 
(focal versus diffuse) for the study population (n=120)
* significant difference (p<0.05)
Figure 6. The 5-year overall survival curve for thymidylate synthase (TS) staining pattern 
(focal versus diffuse) for 98 patients treated with chemotherapy
in 70 percent of patients, in our material the diffuse TS
staining pattern was found in 13 of 17 patients treated
with palliative chemotherapy (76.5%). The TS expression
in the metastasis would be different than in the primary
tumor, which could determine the response to 5-FU-
based chemotherapy.
Gorlick et al. have demonstrated significantly higher
TS expression in pulmonary metastases than in liver
metastases in advanced colorectal cancer [19]. Cascinu
et al., on the contrary, have observed lower TS expression
in liver metastases than in other abdominal metastases in
patients with advanced colon cancer [12]. In addition,
the investigation performed by Findlay and others has
revealed that the TS level in the primary tumor could
not serve as the predictor of response to 5FU-based
chemotherapy in case of the disease dissemination [17].
Summarizing, the results of the above studies suggest
that TS expression assessed on the primary tumor may
not correlate with that measured in the metastasis of the
same patient. Similar observation can relate to patients
with locally advanced colorectal cancer, where the TS
expression in the primary tumor may differ from the TS
level on the site of micrometastases. So estimation of the
TS expression in the primary tumor would not predict
the response of micrometastases to the adjuvant
chemotherapy.
Thus the issue of the optimal selection of patients for
adjuvant treatment is still vague.
The results of our study suggest that the diffuse TS
staining pattern may help in the identification of high
risk colorectal cancer patients who should receive more
aggressive treatment. Such patients seem to be good
candidates for chemotherapy regimens with irinotecan
or oxaliplatin.
In conclusion, our study has confirmed the prog-
nostic value of the TS staining pattern in colorectal
cancer. Predictive role of TS expression assessed on the
primary tumors still needs future investigations.
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